focus -WSS

focus

author：knowledge 2025-08-12 09:08:37 - browse：475

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： 15 die by electrocution after transformer explodes in northern India

WSS

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

US soldier in North Korean custody after crossing DMZ line

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Flagship, Pfizer team up in deal worth up to $7 billion

15 die by electrocution after transformer explodes in northern India

Twill hunts for pharma partner to market its depression app

hotspot

focus

explore

Alkermes shareholders re

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

23andMe had bad news about my health. I wish a person had delivered it

Ultragenyx gene therapy for rare liver ailment succeeds in late

Alkermes shareholders re

With trial win, GSK could get blood cancer drug back on market

Cancer drug shortages should be causing more outrage

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Hollywood unions extend contract negotiations for actors

ER docs worry over extreme heat as a 'mass casualty event'

leisure time

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Robert Kennedy Jr.'s presidential campaign attracts GOP

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Innovation in antibiotics is ailing. 'Brain drain' may kill it

knowledge

hotspot

knowledge

focus